335 related articles for article (PubMed ID: 24727987)
1. Successes and limitations of targeted cancer therapy in lung cancer.
Suda K; Mitsudomi T
Prog Tumor Res; 2014; 41():62-77. PubMed ID: 24727987
[TBL] [Abstract][Full Text] [Related]
2. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
3. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
4. [Development of molecular targeted therapies in lung cancers].
Suda K; Mitsudomi T
Nihon Geka Gakkai Zasshi; 2014 May; 115(3):130-6. PubMed ID: 24946519
[TBL] [Abstract][Full Text] [Related]
5. [Molecular mechanisms of targeted drug resistance in lung cancer and its therapeutic strategy].
Yano S
Nihon Rinsho; 2015 Aug; 73(8):1378-83. PubMed ID: 26281693
[TBL] [Abstract][Full Text] [Related]
6. Resistance to Therapy.
Rivera G; Wakelee HA
Cancer Treat Res; 2016; 170():183-202. PubMed ID: 27535395
[TBL] [Abstract][Full Text] [Related]
7. [Driver gene mutation and targeted therapy of lung cancer].
Mitsudomi T
Gan To Kagaku Ryoho; 2013 Mar; 40(3):285-90. PubMed ID: 23507588
[TBL] [Abstract][Full Text] [Related]
8. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
[TBL] [Abstract][Full Text] [Related]
9. CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation.
Suda K; Mizuuchi H; Murakami I; Uramoto H; Tanaka F; Sato K; Takemoto T; Iwasaki T; Sekido Y; Yatabe Y; Mitsudomi T
Lung Cancer; 2014 Aug; 85(2):147-51. PubMed ID: 24939008
[TBL] [Abstract][Full Text] [Related]
10. Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny.
Suda K; Mizuuchi H; Maehara Y; Mitsudomi T
Cancer Metastasis Rev; 2012 Dec; 31(3-4):807-14. PubMed ID: 22736441
[TBL] [Abstract][Full Text] [Related]
11. [Personalized therapy of lung cancer - current standard and future challenges].
Riedel R; Wolf J
Dtsch Med Wochenschr; 2017 Nov; 142(22):1660-1668. PubMed ID: 29078211
[TBL] [Abstract][Full Text] [Related]
12. Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.
Califano R; Abidin A; Tariq NU; Economopoulou P; Metro G; Mountzios G
Cancer Treat Rev; 2015 May; 41(5):401-11. PubMed ID: 25842168
[TBL] [Abstract][Full Text] [Related]
13. Population-level effect of molecular testing and targeted therapy in patients with advanced pulmonary adenocarcinoma: a prospective cohort study.
Schwegler C; Kaufmann D; Pfeiffer D; Aebi S; Diebold J; Gautschi O
Virchows Arch; 2018 Apr; 472(4):581-588. PubMed ID: 29198034
[TBL] [Abstract][Full Text] [Related]
14. [Research Progress of Targeted Therapy for BRAF Mutation
in Advanced Non-small Cell Lung Cancer].
Liu X; Zhong D
Zhongguo Fei Ai Za Zhi; 2018 Aug; 21(8):635-640. PubMed ID: 30172272
[TBL] [Abstract][Full Text] [Related]
15. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F
Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy for NSCLC with driver mutations.
Minuti G; D'Incecco A; Cappuzzo F
Expert Opin Biol Ther; 2013 Oct; 13(10):1401-12. PubMed ID: 23930754
[TBL] [Abstract][Full Text] [Related]
17. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.
Tan AC; Tan DSW
J Clin Oncol; 2022 Feb; 40(6):611-625. PubMed ID: 34985916
[TBL] [Abstract][Full Text] [Related]
18. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
Toyokawa G; Seto T
Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
[TBL] [Abstract][Full Text] [Related]
19. Personalized therapy for lung cancer.
Moreira AL; Eng J
Chest; 2014 Dec; 146(6):1649-1657. PubMed ID: 25451351
[TBL] [Abstract][Full Text] [Related]
20. Emerging targeted therapies in non-small cell lung cancer.
Khanal N; Ganti AK
Expert Rev Anticancer Ther; 2016; 16(2):177-87. PubMed ID: 26618563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
